Abstract: The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
March 15, 2022
Assignee:
CEMM—Forschungszentrum für Molekulare Medizin GmbH
Inventors:
Robert Kralovics, Thorsten Klampfl, Heinz Gisslinger
Abstract: A method of analyzing a biological sample from a subject that has a tumor or cancer, comprising: determining, for target cells having a phenotype of interest spatial resolution of the target cells, density of the spatially resolved target cells in the sample; and proximity between spatially resolved target cells of interest in the sample; and determining an overall score based at least in part on the preceding parameters. A method for identifying a patient as a responder to single agent anti-PD-1 or anti-PD-L1 therapy is provided. Similar methods are provided for detecting adaptive immune resistance, the presence of cancer in a patient sample, determining efficacy of cancer therapy, and determining response to and monitoring the efficacy of cancer therapy.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
March 15, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention relates to the sialyltransferase ST3GAL6 for use as a biomarker for multiple myeloma, and especially as a marker for myelomas with inferior survival rates. The inventors have shown that glycosylation gene expression is dysregulated in Multiple Myeloma and that overexpression of the sialyltransferase ST3GAL6 is associated with inferior survival rates in patients.
Type:
Grant
Filed:
May 17, 2017
Date of Patent:
February 8, 2022
Assignee:
National University of Ireland, Galway
Inventors:
Siobhan Glavey, Lokesh Joshi, Michael O'Dwyer
Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.
Type:
Grant
Filed:
December 12, 2018
Date of Patent:
February 1, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The invention relates to a novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.
Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.
Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
January 18, 2022
Assignee:
Xencor, Inc.
Inventors:
Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
Abstract: The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
January 11, 2022
Assignee:
The Regents of the University of Michigan
Inventors:
James J. Moon, Rui Kuai, Anna A. Schwendeman, Jutaek Nam
Abstract: Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells.
Abstract: The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (CIN) genes including HDGF, KIAA0286, RFC4, and MSH6, collectively referred to as CIN4. Patients that have a low CIN4 score benefit from anthracycline treatment compared patients with a high CIN4 score.
Type:
Grant
Filed:
July 15, 2015
Date of Patent:
January 4, 2022
Assignee:
Ontario Institute for Cancer Research
Inventors:
Melanie Spears, John Bartlett, Fouad Yousif, Paul Boutros
Abstract: Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
December 21, 2021
Assignee:
BEIGENE, LTD.
Inventors:
Tong Zhang, Liu Xue, Qi Liu, Hao Peng, Min Wei, Kang Li
Abstract: The present invention includes a composition and a method of modulating an immune response with a composition that comprises an anti-BAFF receptor antibody or binding fragment thereof that is bound or conjugated to an siRNA, and shRNA, or both, that targets a BAFF receptor mRNA.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
December 14, 2021
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
Type:
Grant
Filed:
November 16, 2020
Date of Patent:
December 7, 2021
Assignee:
Sanofi
Inventors:
Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
Type:
Grant
Filed:
November 14, 2017
Date of Patent:
December 7, 2021
Assignee:
APROGEN MEDICINES INC.
Inventors:
Yoo Ri Moon, Sangsoon Yoon, Jeong Won Hong, Eun Jung Kim, Da Bin Choi
Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
Type:
Grant
Filed:
October 12, 2016
Date of Patent:
November 2, 2021
Assignee:
Astellas Deutschland GmbH
Inventors:
Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
Abstract: The present invention relates to a method for discrimination of p16INK4a overexpressing metaplasias from neoplastic or preneoplastic p16INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4a based detection of anogenital lesions in cytological testing procedures.
Type:
Grant
Filed:
February 19, 2019
Date of Patent:
October 26, 2021
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Ruediger Ridder, Magnus Von Knebel Doeberitz, Peter Martin